glp-1 receptor agonists benefits in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP1 Receptor Agonists—Effects beyond Obesity

F.MahmoudiM.WangZ.WangR

In SURPASS 4 The risk of suffering from any major adverse cardiovascular event MACE-4 and MACE-3 (including myocardial infarction, stroke, hospitalization for angina, and all-cause death) with the highest dose of tirzepatide (15 mg per week) has been estimated at 050 (026095), which was intended to provide initial proof of the cardiovascular safety of tirzepatide [2, 5]

B.WangB.GardnerE

In addition, the pathogenesis of DR is complex, involving factors such as retinal microvascular damage induced by hyperglycemia, vascular endothelial dysfunction, inflammatory responses, and oxidative stress

Still in Phase 3 clinical trials, early results show unprecedented weight loss, with some participants losing over 24 percent of body weight

R., Aune D., et al., Body Mass Index and Survival in Women With Breast CancerSystematic Literature Review and MetaAnalysis of 82 FollowUp Studies, Annals of Oncology 25 (2014): 19011914